Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $12.50 Average Price Target from Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $12.6250.

Several research firms have commented on CATX. HC Wainwright lifted their price objective on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. B. Riley Financial increased their target price on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Piper Sandler started coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target on the stock. Finally, UBS Group increased their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th.

Perspective Therapeutics Stock Down 3.6%

NYSEAMERICAN:CATX opened at $4.07 on Friday. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The business has a 50 day simple moving average of $4.55 and a 200-day simple moving average of $3.47. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The company had revenue of $0.04 million for the quarter. As a group, research analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Opaleye Management Inc. bought a new stake in shares of Perspective Therapeutics during the fourth quarter worth $3,257,000. Patient Square Capital LP grew its holdings in shares of Perspective Therapeutics by 224.3% in the fourth quarter. Patient Square Capital LP now owns 1,132,815 shares of the company’s stock worth $3,115,000 after purchasing an additional 783,492 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Perspective Therapeutics by 139.9% in the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock worth $2,695,000 after purchasing an additional 458,323 shares during the last quarter. Marshall Wace LLP purchased a new position in Perspective Therapeutics in the 4th quarter worth about $1,119,000. Finally, JPMorgan Chase & Co. increased its stake in Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after buying an additional 405,612 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.